[go: up one dir, main page]

UY31346A1 - Compuestos que tienen actividad en el receptor m1 y sus usos en medicina - Google Patents

Compuestos que tienen actividad en el receptor m1 y sus usos en medicina

Info

Publication number
UY31346A1
UY31346A1 UY31346A UY31346A UY31346A1 UY 31346 A1 UY31346 A1 UY 31346A1 UY 31346 A UY31346 A UY 31346A UY 31346 A UY31346 A UY 31346A UY 31346 A1 UY31346 A1 UY 31346A1
Authority
UY
Uruguay
Prior art keywords
compounds
medicine
receiver
activity
medicaments
Prior art date
Application number
UY31346A
Other languages
English (en)
Inventor
Graeme Irvine Stevenson
Dale James Johnson
Vincenzo Garzya
Paul Adrian Wyman
David Gwyn Cooper
Dr Ian Thomson Forbes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40029139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0718419A external-priority patent/GB0718419D0/en
Priority claimed from GB0814902A external-priority patent/GB0814902D0/en
Application filed filed Critical
Publication of UY31346A1 publication Critical patent/UY31346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de fórmula (I) o una sal de los mismos: donde R4, R5, R6, Q, A, Y y R son como se han definido en la descripción. Se describen usos de los compuestos como medicamentos y en la fabricación de medicamentos para tratar trastornos psicóticos, alteraciones cognitivas y enfermedad de Alzheimer. La invención también describe composiciones farmacéuticas que comprenden los compuestos.
UY31346A 2007-09-20 2008-09-18 Compuestos que tienen actividad en el receptor m1 y sus usos en medicina UY31346A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718419A GB0718419D0 (en) 2007-09-20 2007-09-20 Compounds
GB0814902A GB0814902D0 (en) 2008-08-14 2008-08-14 Compounds

Publications (1)

Publication Number Publication Date
UY31346A1 true UY31346A1 (es) 2009-04-30

Family

ID=40029139

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31346A UY31346A1 (es) 2007-09-20 2008-09-18 Compuestos que tienen actividad en el receptor m1 y sus usos en medicina

Country Status (9)

Country Link
US (1) US8299257B2 (es)
EP (1) EP2194983A1 (es)
JP (1) JP2010539218A (es)
AR (1) AR068480A1 (es)
CL (1) CL2008002808A1 (es)
PE (1) PE20091194A1 (es)
TW (1) TW200930367A (es)
UY (1) UY31346A1 (es)
WO (1) WO2009037296A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
FR2909090B1 (fr) * 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
KR20100016620A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체
JP2010525013A (ja) * 2007-04-23 2010-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしてのピリジン誘導体
CA2682671C (en) * 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
US8278328B2 (en) * 2007-09-20 2012-10-02 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
EP2310374B1 (en) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
US8895562B2 (en) * 2008-07-31 2014-11-25 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
CN112812782B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种环己烷类苯并噁唑液晶化合物、制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013262A1 (en) * 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) * 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CN1561212A (zh) * 2001-10-02 2005-01-05 阿卡蒂亚药品公司 作为毒蕈碱试剂的苯并咪唑啉酮衍生物
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
JP5209479B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
US8278328B2 (en) * 2007-09-20 2012-10-02 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine

Also Published As

Publication number Publication date
WO2009037296A1 (en) 2009-03-26
CL2008002808A1 (es) 2010-01-15
AR068480A1 (es) 2009-11-18
EP2194983A1 (en) 2010-06-16
TW200930367A (en) 2009-07-16
PE20091194A1 (es) 2009-09-05
US20100210687A1 (en) 2010-08-19
JP2010539218A (ja) 2010-12-16
US8299257B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
EA200901373A1 (ru) Аминогетероциклические соединения
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
UY32391A (es) Compuestos amino-heterocíclicos
DOP2006000141A (es) Derivados de oxindol
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
PA8585001A1 (es) Compuestos de tiazol para el tratamiento de transtornos neurodegenerativos
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
UY30282A1 (es) Compuestos quimicos
GT200500307A (es) Compuestos quimicos
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
CU20090058A7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
ATE523495T1 (de) Substituierte pyrazolinverbindungen, deren herstellung und verwendung als medikamente